Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the shares. Insulet’s Q4 revenue was above estimates and 2025 revenue guidance was largely in-line with consensus, the analyst tells investors in a research note. Insulet has a unique competitive position, with its form factor, PBM relationships, and type 2 label expansion, and these factors will continue to support the company’s market leadership, Raymond James argues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $293 from $245 at Stifel
- Insulet price target raised to $310 from $300 at BTIG
- Insulet’s Strong Performance and Growth Potential: Analyst Recommends Buy Rating
- Insulet price target raised to $310 from $285 at Piper Sandler
- Insulet price target raised to $325 from $317 at Morgan Stanley